The Lancet

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

nDepartment of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, India oDepartment of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India ...
ascopubs.org

Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up

Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...
ascopubs.org

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT). The ...
ahajournals.org

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains ...
The New York Times

Netanyahu Reveals He Had Prostate Cancer and Underwent Radiation Therapy

The Israeli leader had surgery in 2024 for an enlarged prostate. More recently, follow-up care detected a tumor, his office disclosed on Friday. By David M. Halbfinger Reporting from Jerusalem Prime ...